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Abstract
Accumulating evidence points to altered GABAergic parvalbumin-expressing interneurons and 
impaired myelin/axonal integrity in schizophrenia. Both findings could be due to abnormal 
neurodevelopmental trajectories, affecting local neuronal networks and long-range synchrony and 
leading to cognitive deficits. In this review, we present data from animal models demonstrating 
that redox dysregulation, neuroinflammation and/or NMDAR hypofunction (as observed in 
patients) impairs the normal development of both parvalbumin interneurons and oligodendrocytes. 
These observations suggest that a dysregulation of the redox, neuroimmune, and glutamatergic 
systems due to genetic and early-life environmental risk factors could contribute to the anomalies 
of parvalbumin interneurons and white matter in schizophrenia, ultimately impacting cognition, 
social competence, and affective behavior via abnormal function of micro- and macrocircuits. 
Moreover, we propose that the redox, neuroimmune, and glutamatergic systems form a “central 
hub” where an imbalance within any of these “hub” systems leads to similar anomalies of 
parvalbumin interneurons and oligodendrocytes due to the tight and reciprocal interactions that 
exist among these systems. A combination of vulnerabilities for a dysregulation within more than 
one of these systems may be particularly deleterious. For these reasons, molecules, such as N-
acetylcysteine, that possess antioxidant and anti-inflammatory properties and can also regulate 
glutamatergic transmission are promising tools for prevention in ultra-high risk patients or for 
early intervention therapy during the first stages of the disease.
© 2014 Elsevier B.V. All rights reserved.
Corresponding author: Kim Q. Do, Center for Psychiatric Neuroscience, Department of Psychiatry, Centre Hospitalier Universitaire 
Vaudois and University of Lausanne, Site de Cery, 1008 Prilly-Lausanne, Switzerland, Kim.Do@chuv.ch, tel: +41 079 556 56 94, 
FAX: +41 21 643 65 62. 
Contributors: PS: wrote the drafts of the manuscript; JHC, AM, DD, POD, MC, and KQD contributed to the writing of the 
manuscript and approved its final version
Conflict of interest: P. O. is employee and stockholder of Pfizer, Inc. All other authors declare no conflict of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Schizophr Res. Author manuscript; available in PMC 2016 January 04.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
parvalbumin interneurons; oligodendrocytes; myelination; N-acetylcysteine; development; 
oxidative stress
Introduction
Schizophrenia is considered a disorder with an important neurodevelopmental component. 
Various genetic and environmental risk factors can affect brain developmental processes 
including maturation of interneurons and oligodendrocytes, which could eventually 
contribute to the emergence of the symptoms during adolescence and early adulthood (Insel, 
2010). Our current understanding of the neurobiological processes involved in schizophrenia 
remains, however, limited. Many hypotheses have been proposed, but a consensus among 
the research community is lacking. Prominent hypotheses include disturbance of 
glutamatergic neurotransmission in the form of hypofunction of NMDA receptors 
(NMDARs) (Coyle et al., 2012; Kantrowitz and Javitt, 2012; Krystal et al., 1994; Steiner et 
al., 2013), neuroinflammation (Meyer, 2013; Potvin et al., 2008; Saetre et al., 2007; van 
Berckel et al., 2008), and redox dysregulation (Clay et al., 2011; Do et al., 2009a, b; Gysin 
et al., 2011; Martins-de-Souza et al., 2011; Yao and Keshavan, 2011). We propose that 
dysregulation of redox homeostasis, neuroimmune, and glutamatergic systems induced by 
different etiological factors constitute, via their reciprocal interactions, one “central hub” as 
a common final pathway contributing to this disorder (Fig. 1). Here, we review the effect of 
dysregulation of each of these systems and their interactions on excitatory/inhibitory balance 
of local neuronal circuits (microcircuits), as well as the connections between distant brain 
areas (macrocircuits). In particular, we propose that dysfunction in these systems has 
deleterious effects on normal development of cortical and hippocampal parvalbumin-
expressing interneurons (PVI), which are essential for fast local neuronal synchronization, 
and on oligodendrocytes, which form myelin sheets around axons providing fast signal 
conduction between brain regions. Anomalies of PVI and oligodendrocytes are indeed 
widely recognized in schizophrenia and considered to contribute to abnormal brain 
connectivity leading to cognitive, affective, and social deficits.
1. A “hub” formed by the redox, glutamatergic, and neuroimmune systems
A dysregulation of the redox, glutamatergic, and neuroimmune systems has all been 
reported in schizophrenia. Genetic and/or environmental risk factors can contribute to 
disturbances within each of these tightly interdependent systems (see Fig. 1 and its legend 
for more details). In particular, redox pathways represent a central node via their numerous 
reciprocal interactions with the glutamatergic and immune systems. Oxidative stress is 
defined as an imbalance between antioxidants and pro-oxidants (reactive oxygen species 
(ROS) and reactive nitrogen species (RNS)), resulting in macromolecular damage. In 
addition, redox signaling plays a key regulating role in many cellular and physiological 
processes (Jones, 2008). A redox dysregulation can affect cell proliferation/differentiation, 
energy metabolism, and neurotransmission via an alteration of redox-sensitive protein 
function, redox-dependent gene expression, and epigenetic mechanisms (Cyr and Domann, 
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2011; Ray et al., 2012; Valko et al., 2007). Several proteins related to glutamatergic 
neurotransmission contain modulatory redox sites, including glutamine synthase (Mustafa et 
al., 2007), serine racemase (responsible for synthesis of glycine, a NMDAR co-agonist, 
(Pinteaux et al., 1996)), and NMDARs (Choi et al., 2001). While redox state modulates 
NMDAR function, activation of synaptic NMDARs strengthens neuronal antioxidant 
defense mechanisms (Hardingham and Bading, 2010). Moreover, glutathione (GSH), the 
main antioxidant and redox regulator, constitutes a neuronal reservoir of glutamate (Koga et 
al., 2011). These observations indicate that redox and glutamatergic systems are intimately 
dependent. Likewise, oxidative stress is tightly linked to inflammation. Many inflammatory 
mediators are activated by oxidative molecules, while activated immune cells such as 
microglia generate ROS and RNS. The complex interplay between oxidative stress and 
inflammation is in part governed by the reciprocal interactions between the transcription 
factors Nrf2 (whose nuclear translocation induces antioxidant phase II gene transcription) 
and NF-kB (whose translocation to the nucleus promotes transcription of many pro-
inflammatory genes) (Buelna-Chontal and Zazueta, 2013). Finally, an imbalance of the 
immune system may also affect NMDAR function. Human subjects with anti-NMDAR 
encephalitis develop psychosis (Dalmau et al., 2011) and antibodies against NMDAR have 
been reported in patients diagnosed with schizophrenia (Steiner et al., 2013). Moreover, 
inflammatory processes cause increased production of kynurenic acid, an endogenous 
NMDAR antagonist, via dysregulation of tryptophan/kynurenine metabolism (Muller et al., 
2011). Thus, redox, immune, and glutamatergic systems form a triad in which each of its 
elements can influence the others. Diverse genetic vulnerabilities and environmental risk 
factors may affect one element of this triad, impacting in turn the other systems. Because of 
the complex interactions between each element of this triad, it is difficult to untangle the 
respective contribution of each system in the pathophysiology. To our view, the primary 
effector may depend on the specific combination of the genetic vulnerability and 
environmental insults. Therefore, the redox, immune, and glutamatergic systems may be 
considered together as one “central hub” in which a dysregulation in any of them can lead to 
a common pathophysiological condition, such as dysconnectivity via impairment of PVI and 
oligodendrocytes.
2. Parvalbumin interneurons
PVI are GABAergic neurons that form inhibitory synapses onto either the cell body (for 
parvalbumin-expressing basket cells) or the axon initial segment (for parvalbumin-
expressing chandelier cells) of pyramidal neurons (PNs). Basket cells control inputs 
reaching the soma of PNs, while chandelier cells control PN output. PVI, which are 
interconnected via gap junctions (Fukuda et al., 2006) and reciprocal GABAergic synapses, 
constitute a cellular network able to synchronize the excitatory state of large numbers of 
PNs (Bartos et al., 2007). By way of feedback and feedforward inhibition, fast-spiking 
interneurons exert precise temporal control on information that can flow through PNs. These 
interneurons favor summation and transmission of converging inputs arriving synchronously 
onto a PN. By controlling synchronized excitability state of a network of PNs, PVI also 
allow the binding of information that reach these different PNs during a defined and narrow 
time window (Fries et al., 2007). Therefore, PVI strongly influence local neuron-network 
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dynamic. They are critical for high-frequency neuronal synchrony, reflected in gamma band 
oscillations (30–80 Hz) (Cardin et al., 2009; Fuchs et al., 2007; Gulyas et al., 2010; Massi et 
al., 2012; Sohal et al., 2009), but can also modulate neuronal activity in the theta band (4–8 
Hz), as well as theta-gamma coupling (Korotkova et al., 2010; Wulff et al., 2009). The 
maturation of PVI and their associated extracellular matrix defines a critical period of 
cortical network plasticity during postnatal development (Morishita and Hensch, 2008). 
Moreover, plasticity within the basket-cell network contributes to memory learning, 
consolidation and retrieval (Donato et al., 2013) and PVI promote neuronal progeny survival 
and development in the hippocampus (Song et al., 2013). Furthermore, in prefrontal cortical 
regions, heavily implicated in schizophrenia pathophysiology, PVI mature during 
adolescence (Tseng and O’Donnell, 2007; O’Donnell, 2011) and is therefore a neural 
population with a protracted developmental trajectory that could explain the peri-adolescent 
onset of schizophrenia symptoms.
2.1. Evidence for abnormal PVI in schizophrenia
Compelling evidence suggests an imbalance between glutamatergic excitation and 
GABAergic inhibition in schizophrenia (Lisman et al., 2008; O’Donnell, 2011). Anomalies 
associated with PVI constitute a hallmark of the disease, including reduced density of 
parvalbumin-immunoreactive cells in the hippocampal formation (Wang et al., 2011; Zhang 
and Reynolds, 2002) and alterations at the level of basket and chandelier cells in the 
dorsolateral prefrontal cortex (DLPFC) of post-mortem brains (Lewis et al., 2012). These 
alterations include reduced expression of parvalbumin and GAD67 (isoform of glutamic 
acid decarboxylase, the GABA synthesizing enzyme), changes in their pre- and postsynaptic 
terminals (Lewis et al., 2012), and reduced expression of Kv3.1-containing K+ channels, 
which play a critical role in their fast-spiking properties (Yanagi et al., 2014). Moreover, the 
extracellular matrix (perineuronal net: PNN) that surrounds many PVI is reduced in DLPFC 
(Mauney et al., 2013), entorhinal cortex, and amygdala of schizophrenia patients 
(Pantazopoulos et al., 2010). Current data suggest an impaired maturation of PVI rather than 
a deficit due to the chronicity of the illness. The DLPFC of young patients already has low 
expression levels of parvalbumin and GAD67 (Hoftman et al., 2013), and gene expression 
pattern in PVI of schizophrenia individuals resembles that of non-mature cells (Gandal et al., 
2012). Therefore, dysfunction of the PVI-associated network may lead to abnormal neuronal 
activity in patients, including oscillatory activity within theta, beta and gamma ranges 
(McNally et al., 2013; Uhlhaas and Singer, 2010, 2012). Ultimately, interneuron dysfunction 
could contribute to altered sensory perception (Atallah et al., 2012), deficits in working 
memory (Korotkova et al., 2010; Roux et al., 2012), attention (Rouhinen et al., 2013), and 
learning (Carlen et al., 2012).
2.2. Mechanisms underlying abnormal PVI
Recent studies have revealed anomalies in hippocampal and/or prefrontal PVI in many 
preclinical animal models aiming to reproduce genetic vulnerabilities (Carlson et al., 2011; 
Fazzari et al., 2010; Hikida et al., 2007; Wen et al., 2010) or environmental risk factors 
(Brown, 2011) such as prenatal maternal stress (Stevens et al., 2013), maternal and perinatal 
immune challenge (Jenkins et al., 2009; Meyer et al., 2008), hypoxia (Dell’Anna et al., 
1996; Komitova et al., 2013), early-life iron deficiency (Callahan et al., 2013), maternal 
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separation (Brenhouse and Andersen, 2011) and social isolation (Harte et al., 2007; 
Schiavone et al., 2009). These developmental insults cause oxidative stress (Do et al., 
2009b; Walter et al., 2002) and/or neuroinflammation (Brenhouse and Andersen, 2011; 
Garate et al., 2013; Kaur et al., 2013). Furthermore, non-genetic developmental models also 
result in altered prefrontal PVI (Lodge et al., 2009; Tseng et al., 2008). In rats with a 
neonatal ventral hippocampal lesion, the normal peri-adolescent maturation of PVI is 
impaired (Tseng et al., 2008), and in this model PVI show evidence of oxidative stress prior 
to the onset of behavioral deficits (O’Donnell et al., 2011). Below, we present evidence that 
PVI are particularly affected during their development by oxidative stress, 
neuroinflammation, and NMDAR hypofunction.
2.2.1. Vulnerability to redox dysregulation/oxidative stress—To support high-
frequency neuronal synchronization, fast-spiking PVI are energy demanding. This requires 
optimal mitochondrial performance (Kann et al., 2011) with enhanced metabolic activity and 
oxidative phosphorylation (Harris et al., 2012) leading to elevated mitochondria-generated 
ROS. Consequently, PVI need well-regulated antioxidant systems to neutralize ROS and 
maintain proper redox state. Interestingly, the power of β/γ neuronal activity is positively 
correlated with blood GSH levels in patients (Ballesteros et al., 2013). These cells are 
vulnerable to redox dysregulation, whether induced by a compromised antioxidant system or 
ROS overproduction. In an animal model with low GSH content, as reported in the brain of 
some schizophrenia patients (Do et al., 2000; Gawryluk et al., 2011; Yao et al., 2006), there 
is a deficit in prefrontal and hippocampal PVI, impairing high-frequency neuronal 
synchronization (Cabungcal et al., 2013a; Cabungcal et al., 2013b; Steullet et al., 2010). 
Interestingly, an inhibition of GSH synthesis restricted to PVI is sufficient to affect these 
interneurons (Cabungcal et al., 2013b) and oxidative stress precedes the PVI deficit (Steullet 
et al., 2010). PVI can also be affected when antioxidant systems other than GSH are 
compromised. A reduced number of parvalbumin-immunoreactive cells is observed in mice 
with a deletion for the selenoprotein P, a glycoprotein with antioxidant properties (Pitts et 
al., 2012) or for PGC-1α, a transcription factor regulating mitochondria function and ROS 
metabolism (Lucas et al., 2010). Furthermore, superoxide overproduction by NADPH 
oxidase (NOX) is also deleterious to PVI (Behrens et al., 2007), and NOX inhibition 
prevents the PVI impairment induced by social isolation (Schiavone et al., 2009).
Most importantly, prefrontal cortical PVI are more vulnerable to a redox dysregulation 
during postnatal development than later in life. A pharmacologically induced transient 
postnatal deficit in GSH causes both immediate and long-term decreased density of 
parvalbumin-immunoreactive cells in the anterior cingulate cortex (ACC) (Cabungcal et al., 
2006; Kulak et al., 2013; Steullet et al., 2011). In mice with a chronic GSH deficit (Gclm 
KO mice, Kulak et al., 2012), administration of a dopamine re-uptake inhibitor 
(GBR-12909), which partially mimics dopamine release during psychosocial stress (Lataster 
et al., 2011) and produces ROS via the catabolism of dopamine (Cadet and Brannock, 1998; 
Rabinovic and Hastings, 1998), decreases permanently the density of parvalbumin-
immunoreactive cells in the ACC when applied during postnatal development, but not 
adulthood (Cabungcal et al., 2013a). Thus, immature PVI may have a less robust antioxidant 
defense system than mature cells. Alternatively, molecular mechanisms underlying PVI 
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maturation are highly sensitive to a redox imbalance. Interestingly, the vulnerability of 
prefrontal immature PVI is associated with the absence of fully mature PNN, which protects 
these cells against oxidative stress (Cabungcal et al., 2013b). However, excess of oxidative 
stress also affects PNN (Cabungcal et al., 2013b), which can in turn impact PVI. Indeed, the 
maturation and phenotypic maintenance of PVI require incorporation of a non-cell 
autonomous homeobox protein, Otx2, through its affinity with PNN (Beurdeley et al., 2012; 
Miyata et al., 2012).
The implication of redox dysregulation/oxidative stress for the developmental impairment of 
PVI has been further substantiated by recent studies on experimental neurodevelopmental 
models that do not directly manipulate the redox system. First, the widely studied neonatal 
ventral hippocampal lesion model also displays oxidative stress and PVI defect, both of 
which are prevented by a juvenile and adolescence treatment with the antioxidant and GSH 
precursor, N-acetylcysteine (NAC) (O’Donnell et al., 2011; Sullivan and O’Donnell, 2012). 
Second, a single injection of the DNA-alkylating agent methylazoxymethanol acetate 
(MAM) during pregnancy, which also causes schizophrenia phenotypes in adult rats, leads 
to anomalies in PVI and neuronal synchronization (Lodge et al., 2009; Penschuck et al., 
2006). MAM-treated rats have also decreased brain GSH levels (Cleland et al., 2013, 
abstract Neuroscience Meeting). Collectively, these studies demonstrate that a redox 
dysregulation during a critical developmental period can disrupt normal maturation of PVI.
2.2.2. Vulnerability to NMDAR hypofunction—Numerous studies show that NMDAR 
blockade in adults disrupts excitatory/inhibitory balance in cortical circuits, affecting PVI 
(Behrens et al., 2007) and neuronal network activity (Carlen et al., 2012; Homayoun and 
Moghaddam, 2007; Kocsis et al., 2013; Korotkova et al., 2010; Lazarewicz et al., 2010). 
However, PVI are especially vulnerable to NMDAR hypofunction during development 
(Abekawa et al., 2007; Powell et al., 2012; Wang et al., 2008; Wang et al., 2013). Inhibition 
of NMDARs during early life causes a persistent decrease in number of parvalbumin-
immunoreactive cells without cell death (Powell et al., 2012), suggesting that disruption of 
NMDAR-mediated signaling impairs maturation of these cells. Indeed, the maturation of 
PVI is activity-dependent (Chattopadhyaya et al., 2004; Patz et al., 2004). Calcium entrance 
is necessary for the maturation of PNN (Dityatev et al., 2007) and PVI (Jiang and Swann, 
2005; Kinney et al., 2006), and activation of NR2A-containing NMDARs contributes to the 
molecular signaling that leads to the maturation of these cells (Kinney et al., 2006; Zhang 
and Sun, 2011).
2.2.3. Interactions between NMDAR hypofunction and redox dysregulation—It 
is intriguing that NMDAR hypofunction and redox dysregulation impair PVI maturation in 
similar ways. This raises the possibility that both mechanisms interfere with the maturation 
of PVI cells via related molecular mechanisms. Interestingly, synaptic NMDAR activation 
boosts GSH, thioredoxin, and peroxiredoxin systems via calcium-mediated signaling 
involving activation of CREB and inhibition of FOXO (Hardingham and Bading, 2010; 
Papadia et al., 2008). The work from Nakazawa and colleagues indicates that impaired 
maturation of PVI induced by NMDAR hypofunction is due to a redox dysregulation. When 
applied during postnatal development, a deletion of the NR1 subunit of NMDARs in a 
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subpopulation of interneurons (including most PVI) leads to parvalbumin and GAD67 
expression deficit along with oxidative stress in PVI (Belforte et al., 2010; Jiang et al., 
2013). In these mice, social isolation exacerbates oxidative stress and PVI deficits, both of 
which are prevented by a NOX inhibitor (Jiang et al., 2013). In NOX-2 knockout mice, PVI 
are protected from a postnatal ketamine treatment, indicating a crucial role of NOX in the 
PVI impairment following early-life blockade of NMDAR (Powell et al., 2012). However, 
the lack of NMDAR-mediated signaling also causes a reduction in PGC-1α levels and 
expression of several antioxidant enzymes (Jiang et al., 2013), and decreases GSH levels 
(Stojkovic et al., 2012). These observations suggest that NMDAR hypofunction can weaken 
antioxidant defenses, contributing to a redox dysregulation and affecting cell maturation. 
The downregulation of antioxidant systems by NMDAR blockade may be particularly 
significant in PVI of young individuals, since NMDAR-mediated postsynaptic responses are 
stronger in immature compared to mature PVI (Rotaru et al., 2011; Wang and Gao, 2009, 
2010). However, a redox dysregulation can also downregulate NMDAR function on its own. 
Functional down-regulation of NMDARs by oxidative conditions can occur via either 
extracellular redox-sensitive sites located on NR1 and NR2A subunits (Choi et al., 2001; 
Kohr et al., 1994) or by Ca2+/calmodulin-dependent protein kinase II (Bodhinathan et al., 
2010). A transient postnatal GSH deficit results in NMDAR hypofunction (Steullet et al., 
2006) and impairs PVI (Cabungcal et al., 2006). Therefore, redox dysregulation and NMDA 
receptor hypofunction during postnatal development can interact synergistically, creating a 
vicious circle that is particularly detrimental for PVI.
2.2.4. Vulnerability to neuroinflammation—Because of the tight link between 
oxidative stress and inflammation, it is not surprising that pro-inflammatory molecules 
affect PVI. Interleukin-6 mediates ketamine-induced NOX upregulation and subsequently 
PVI deficits (Behrens et al., 2008). A genome-wide profiling and immunohistological study 
revealed that reduced PVI density in schizophrenia patients is associated with two modules 
of genes differentially expressed in patients compared to healthy subjects, among which are 
many immune/inflammation-related genes (Hwang et al., 2013). Early-life pro-inflammatory 
conditions, such as maternal and neonatal immune challenges, cause a persistent decrease in 
number of prefrontal and/or hippocampal parvalbumin-immunoreactive interneurons 
(Jenkins et al., 2009; Meyer et al., 2008). This deleterious effect could result from a redox 
dysregulation as maternal immune challenge transiently decreases GSH and vitamin E levels 
and increase oxidative stress in the hippocampus (Lante et al., 2007). A reduced number of 
hippocampal and prefrontal parvalbumin-immunoreactive interneurons is also observed in 
Schnurri-2 KO mice, a genetic model for enhanced neuroinflammation via increased NF-
kB-dependent gene expression (Takao et al., 2013). These mice show increased expression 
of inflammation-related genes and NOX, which affects PVI. The PVI impairment following 
maternal separation can be prevented by non-steroidal anti-inflammatory drugs (Brenhouse 
and Andersen, 2011). Nevertheless, the possibility that a ROS scavenger can also protect 
PVI against the effect of maternal separation cannot be excluded. These data clearly show 
that neuroinflammation impacts PVI, but the specific role of pro-inflammatory molecules 
and oxidative stress remains to be established. A combination of vulnerability for pro-
inflammatory conditions and redox dysregulation due to environmental and genetic factors 
may be particularly deleterious for PVI. This combination has been demonstrated in 
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transgenic mice expressing a putative dominant-negative disrupted in schizophrenia 1 (DN-
DISC1), which display enhanced prefrontal oxidative stress (Johnson et al., 2013) and shows 
stronger PVI deficits following a postnatal immune challenge (Ibi et al., 2010).
To conclude, PVI are particularly vulnerable to redox dysregulation/oxidative stress, 
NMDAR hypofunction, and neuroinflammation during early development. Genetic 
vulnerabilities and environmental insults that would affect homeostasis of either redox, or 
glutamatergic, or neuroimmune system could affect the other systems with amplified 
negative consequences on PVI maturation and subsequently on neuronal network 
synchronization and information processing.
3. Oligodendrocytes/myelination
3.1. Evidence for impaired oligodendrocytes/myelination in schizophrenia
Oligodendrocytes and myelination are clearly impaired in schizophrenia (Chew et al., 2013; 
Davis et al., 2003; Takahashi et al., 2011). The observations supporting this claim include 
decreased expression of oligodendrocyte-related genes (Hakak et al., 2001; Katsel et al., 
2005; Tkachev et al., 2003), impairment of oligodendrocyte maturation (Kerns et al., 2010), 
reduced number and/or density of oligodendrocytes in gray and white matter (Byne et al., 
2008; Hof et al., 2003; Uranova et al., 2004), apoptotic oligodendrocytes and ultrastructural 
alterations in myelinated fibers (Uranova et al., 2001). The anomalies at the level of myelin/
axonal integrity increase with illness duration (Uranova et al., 2011). Studies using magnetic 
resonance techniques such as diffusion tensor imaging (DTI) also suggest abnormal white 
matter along different fiber tracts, including within and between frontal and temporal areas 
(Fitzsimmons et al., 2013). Although less consistent than in chronic patients, white matter 
anomalies are observed in ultra high-risk subjects and first-episode patients (Fitzsimmons et 
al., 2013; Kyriakopoulos and Frangou, 2009), suggesting a neurodevelopmental component 
for this impairment. Oligodendrocytic and myelination anomalies in schizophrenia could 
affect axonal integrity and conduction velocity (Whitford et al., 2011), with the consequence 
of disrupting temporal control of long-range brain synchronization.
3.2. Mechanisms underlying impaired oligodendrocytes/myelination
Genes related to oligodendrocytes and myelination have been associated with schizophrenia 
(Takahashi et al., 2011), suggesting that white matter anomalies in this disorder could have a 
direct genetic origin. However, other mechanisms could also impact white matter integrity. 
Perinatal insults and psychosocial stress during childhood and adolescence are correlated 
with structural changes in white matter (Chew et al., 2013; Eluvathingal et al., 2006; Huang 
et al., 2012). In rodents, early-life insults, most of which cause PVI impairment, also affect 
oligodendrocytes and myelination. These insults include maternal and early postnatal 
immune challenge (Fan et al., 2005; Paintlia et al., 2008), perinatal hypoxia (Oorschot et al., 
2013), hypoxia-ischemic insults (Robinson et al., 2005), and social isolation (Liu et al., 
2012; Makinodan et al., 2012). These observations suggest that some of the biological 
causes for the developmental PVI and white matter anomalies could be similar.
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3.3.1. Vulnerability to redox dysregulation/oxidative stress—In vitro studies show 
that oligodendrocytes are susceptible to oxidative stress due to their high metabolic activity 
and iron content combined with low antioxidant levels (Back et al., 1998; Baud et al., 2004; 
Fragoso et al., 2004). Furthermore, the intracellular redox state controls the proliferation and 
differentiation of oligodendrocytes (Li et al., 2007; Smith et al., 2000; Do et al., 2012), and 
low GSH levels affect oligodendrocyte maturation (French et al., 2009). Peripubertal Gclm 
KO mice (which have low brain GSH content) present a deficit in myelin-associated 
proteins and mature oligodendrocytes in the ACC (Monin et al., 2013, abstract Neuroscience 
Meeting, 255.03). This deficit, which recovers in adulthood, is accompanied by an increase 
in prefrontal N-acetylaspartate (das Neves Duarte et al., 2012), suggesting an impaired 
myelin lipid synthesis during prefrontal cortical maturation (Kulak et al., 2013). 
Interestingly during this period, genes associated with myelin and lipid synthesis, 
antioxidant response systems, mitochondria function and glycolysis are highly expressed 
(Harris et al., 2009). Therefore, a proper redox state controlled by GSH may be critical for 
adequate myelination in prefrontal gray matter during this period of high metabolic activity. 
In addition, a decrease in fractional anisotropy is observed along a few fiber tracts in Gclm 
KO mice, also suggesting white matter anomalies (Corcoba Garcia et al., 2013, abstract 
Neuroscience Meeting, 729.24). Interestingly, we found a positive correlation between GSH 
content in the ACC and fractional anisotropy along the cingulum bundle in young adult 
human subjects (Monin et al., 2013, abstract Neuroscience Meeting, 255.03). Taken 
together, these findings indicate that a redox dysregulation can cause oligodendrocytic 
developmental anomalies and/or delay in gray and white matter which may eventually 
contribute to abnormal myelin sheath and axonal integrity.
3.3.2. Vulnerability to NMDAR dysfunction—Postnatal inhibition of NMDARs causes 
deficit not only in PVI, but also in myelination (Zhang et al., 2012). It is, however, unclear 
whether the myelination impairment results from the redox dysregulation also observed with 
this manipulation (Stojkovic et al., 2012) or from the loss of NMDAR signaling in 
oligodendrocytes. NMDARs are indeed expressed in immature and mature 
oligodendrocytes. Activation of these receptors in oligodendrocytes modulates their 
metabolism, promotes their differentiation from immature into mature stage, and favors 
myelination around axons (Cao and Yao, 2013; Li et al., 2013). Interestingly, NMDAR 
activation promotes the differentiation of cultured oligodendrocytes via NOX-mediated ROS 
(Cavaliere et al., 2012). A combination of redox dysregulation and NMDAR hypofunction 
could be therefore deleterious for oligodendrocyte differentiation and myelination.
3.3.3. Vulnerability to neuroinflammation—Oligodendrocytes, like PVI, are also 
vulnerable to early-life neuroinflammation (Chew et al., 2013). Neonatal administration of 
inflammatory cytokines such as Il-1β reduces the number of developing oligodendrocytes 
(Cai et al., 2004; Fan et al., 2009). Maternal and early postnatal immune challenges impair 
myelination (Fan et al., 2005; Makinodan et al., 2008; Paintlia et al., 2008) and long-range 
synchronization (Dickerson et al., 2010). As microglial cells and cytokines participate in 
normal brain development (Bilbo and Schwarz, 2012; Kettenmann et al., 2013), a 
dysregulation of cytokine-mediated pathways could disrupt normal developmental 
processes. However, current data indicate that redox dysregulation contributes to 
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myelination impairment due to early-life inflammation. Alpha-phenyl-n-tert-butyl-nitrone 
(PBN), a free radical scavenger, protects oligodendrocytes and myelination against neonatal 
immune challenge (Fan et al., 2008). Likewise, NAC prevents this deficit by attenuating the 
dysfunction of peroxisomes, organelles important for ROS detoxification and myelin-lipid 
metabolism (Paintlia et al., 2008). Moreover, the decreased expression of myelin-related 
genes induced by cytokines (Il-1β and TNF-α) in human primary oligodendrocytes is 
blocked by NAC (Jana and Pahan, 2005), suggesting that these inflammatory molecules act 
through redox dysregulation. Finally, the tetracycline antibiotic, minocycline, prevents 
hypomyelination induced by immune challenge, and its protective effect is associated with 
decreased microglial activation, cytokine levels, and oxidative stress (Fan et al., 2005). In a 
genetic model of enhanced pro-inflammation (Schnurri-2 KO mice), the expression of 
myelin-associated proteins is reduced, which could be due to a NOX upregulation (Takao et 
al., 2013). These data show that the impact of early-life neuroinflammation on 
oligodendrocytes and myelination is in part due to the generation of ROS/RNS. Thus as for 
PVI, a vulnerability to redox dysregulation may further exacerbate the deleterious effect of 
pro-inflammatory conditions on myelin integrity.
Taken together, it is remarkable that PVI and oligodendrocytes are affected by similar early-
life insults and by the disruption of redox, neuroimmune and glutamatergic systems. One 
reason for this shared vulnerability could be related to the high metabolic requirement of 
these two cell types. The data compiled in the present review strongly suggest that genetic 
and environmental risk factors, which lead to dysregulation of the “hub” comprised of 
redox, neuroimmune and glutamatergic systems, would invariably affect PVI and white 
matter, and consequently impair long- and short-range neuronal network connectivity. Given 
the pivotal role of PVI, PNN, and myelin in regulating brain plasticity dynamics and active 
epochs (McGee et al., 2005; Miyata et al., 2012; Morishita and Hensch, 2008), the 
dysregulation of this “hub” could yield the slow emergence of clinical symptoms by altering 
the timing of key windows of critical period of brain plasticity (Morishita et al., 2010, 
abstract Neuroscience Meeting, 62.30). Because of the complex interplay between redox, 
immune, and glutamatergic systems, we propose that combinations of genetic and 
environmental risk factors could generate a vicious circle of dysregulation within all these 
systems, ultimately giving rise to abnormal functional and structural connectivity deficits, as 
observed in schizophrenia. We have however to acknowledge that this hypothesis is based 
mostly on observations and experiments in rodent models and postulates that the 
mechanisms are similar in humans. Moreover, we have to emphasize that other systems such 
as the dopamine system known to be implicated in schizophrenia and their reciprocal 
interactions with the proposed “hub” (see: Avshalumov et al., 2007; Baker et al., 2002; 
Kulak et al., 2013; Lodge and Grace, 2011; Meiser et al., 2013; Meyer and Feldon, 2009; 
Moller et al., 2013; Steullet et al., 2008) certainly participate to the pathology. Increasing 
evidence points to altered stress-reactivity as a vulnerability marker for psychosis (Myin-
Germeys et al., 2003; Lataster et al., 2013). The biological mechanism underlying psychotic 
reactivity to stress could be related to hyper-reactivity of dopamine neurons to 
environmental stimuli and stress (Lataster et al., 2011; Mizrahi et al., 2012; Myin-Germeys 
et al., 2005). As dopamine catabolism is known to generate ROS, its excess would induce an 
oxidative stress. Metabolomic approach in cells derived from patients and controls 
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highlights the possibility of using metabolic signatures of reactivity to oxidative stress as 
biomarkers for early psychosis (Fournier et al., 2014).
4. N-acetylcysteine, a potential therapeutic or prevention drug
Novel strategies aiming to regulate redox, immune, and glutamatergic systems could 
therefore be potentially useful to prevent or attenuate developmental anomalies yielding 
schizophrenia pathophysiology. To date, clinical trials using molecules targeting either the 
glutamatergic system (mGluR5, mGluR2/3, glycine site of NMDARs) (Javitt, 2012; 
Kantrowitz and Javitt, 2012; Poels et al., 2014; Vinson and Conn, 2012), the immune (Leza 
et al., 2014; Muller et al., 2013), or antioxidant systems (Leza et al., 2014; Reddy and 
Reddy, 2011) have produced mixed results, some encouraging and others inconclusive. 
Several promising clinical phase III trials aiming to act on the glutamatergic system proved 
inconclusive, but other relatively small scale clinical studies targeting the glycine site of 
NMDAR using D-serine indicate positive effects (Kantrowitz and Javitt, 2012). The efficacy 
of such molecules may however depend on the disease stages but also on patient subgroups. 
Future trials should focuse on unmedicated patients in the early phase of the disease and 
target not only clinical but also biological measures such as mismatch negativity as readouts.
Several antioxidants have been tested in relatively small clinical trials as add-on to 
antipsychotics; this includes vitamin C, vitamin E, and N-acetylcysteine (NAC) (see for 
reviews: Leza et al., 2014; Reddy and Reddy, 2011). Vitamins C and E are non-enzymatic 
antioxidants that scavenge free radicals in the cytosol and at the level of cell membranes, 
respectively. GSH is required for the recycling of oxidized vitamin C into its active form, 
while vitamin C is itself needed to reactivate oxidized vitamin E. Therefore, the efficacy of 
these vitamins may greatly depend on the integrity of the GSH system and the intrinsic 
redox status. This might explain the limited or the lack of efficacy of these compounds. 
However, these vitamins have also been given with some success together with 3-omega 
fatty acids which are key components of membrane phospholipids and have anti-
inflammatory properties among others (see reviews: Leza et al., 2014; Muller et al., 2013; 
Sinn et al., 2010). Interestingly, Bentsen et al. (2013) found that vitamins and 3-omega fatty 
acids, when given separately, can be deleterious in a subgroup of patients. In the present 
review, we will however focus on NAC because it has antioxidant and anti-inflammatory 
properties, and can regulate glutamatergic neurotransmission. NAC is already used as 
antioxidant and GSH precursor to treat GSH deficiency in a wide range of infections, 
genetic defects, and metabolic disorder (Atkuri et al., 2007; Zafarullah et al., 2003). 
Therefore, it represents a safe and potential compound for the prevention or treatment of 
schizophrenia and other psychiatric disorders (Berk et al., 2013). NAC is deacetylated to 
form cysteine, the rate-limiting precursor of GSH, and therefore yields upregulation of GSH 
synthesis when cells face an excess of ROS production. NAC also participates to the control 
of the intracellular redox state by supplying cysteine into the cystine/cysteine redox couple 
(Mandal et al., 2010). In addition, NAC has anti-inflammatory effects, likely via its 
antioxidant properties. Finally, NAC upregulates the activity of the astrocytic cystine/
glutamate antiporter, leading to cellular entry of cystine (which can be reduced to cysteine 
and incorporated into GSH) and extracellular release of glutamate (Bridges et al., 2012). 
This antiporter plays an important role in the regulation of extrasynaptic glutamate levels, 
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which in turn regulate synaptic glutamate release via presynaptic mGluR2/3 (Baker et al., 
2002). Thus, NAC could be useful to reduce synaptic glutamate release and to indirectly 
enhance NMDAR function via its antioxidant and redox regulator properties. Studies on 
several preclinical models and a few clinical trials on schizophrenia patients have recently 
provided a proof of concept that NAC could be a useful therapeutic tool.
4.1. NAC in preclinical models
In mice with a weakened GSH synthesis (Gclm KO mice), NAC prevents PVI and PNN 
deficits induced by an oxidative insult during postnatal development (Cabungcal et al., 
2013a), although it does not increase GSH levels because of the Gclm deletion (das Neves 
Duarte et al., 2012). Furthermore, in young Gclm KO mice, NAC normalizes most of the 
neurochemical profiles, including the glutamime/glutamate ratio known to be altered in a 
similar way in first-episode schizophrenia patients (das Neves Duarte et al., 2012). 
Likewise, NAC reduces oxidative stress, protects prefrontal PVI, and prevents deficits in 
mismatch negativity and pre-pulse inhibition in the neonatal ventral hippocampal lesion rat 
model (O’Donnell et al., 2011; Sullivan and O’Donnell, 2012). NAC also prevents myelin 
impairment following a maternal immune challenge (Paintlia et al., 2008), re-establishes 
normal function of the cystine/glutamate antiporter and GSH levels in MAM-injected rats 
(Cleland et al. 2013, abstract Neuroscience Meeting, 428.10), normalizes extracellular 
glutamate levels and attenuates behavioral anomalies in phencyclidine-treated rats (Lutgen 
et al., 2013), reduces oxidative stress and rescues abnormal behavioral phenotype in 
G72/G30 transgenic mice (Otte et al., 2011), and reverses the social isolation-induced 
changes in corticostriatal monoamine levels (Moller et al., 2013). Thus, NAC has beneficial 
effects on very diverse animal models relevant to schizophrenia.
4.2. NAC in clinical trials
Although beneficial effects of a compound in rodent models do not necessarily translate into 
an efficient therapeutic drug in humans, the few published clinical studies using NAC show 
some promises. In a first randomized double-blind placebo-controlled trial, an add-on 
treatment of NAC in chronic patients diminished negative symptoms and improved global 
functioning (Berk et al., 2008). Two additional studies also demonstrated that chronic 
patients improved with add-on NAC, particularly in their negative symptoms (Bulut et al., 
2009; Farokhnia et al., 2013). In addition, NAC normalized neuronal activity and 
connectivity and improved mismatch-negativity (Lavoie et al., 2008), an auditory-related, 
NMDA-dependent evoked potential typically impaired in schizophrenia (Umbricht et al., 
2000). NAC also increased phase synchronization of neuronal activity over the left parieto-
temporal, the right temporal, and the bilateral prefrontal regions (Carmeli et al., 2012). 
However, the beneficial effect of NAC has to be taken with caution since the current data is 
based on only a few studies showing relatively moderate clinical improvement in chronic 
schizophrenia patients, probably due to the low bioavailability and membrane permeability 
of NAC which enters the brain at a very modest rate (Farr et al., 2003). The development of 
other molecules with better bioavailability and blood-brain barrier permeability are therefore 
needed. As vitamins C and E or 3-omega fatty acids are detrimental for a subgroup of 
patients (Bentsen et al., 2013), it would be also advisable using biomarkers to identify 
patients that would most benefit from an antioxidant treatment. Moreover, NAC or other 
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molecules that target redox, immune, and glutamatergic systems may be more beneficial for 
young subjects at risk than for chronic patients because the defects in PVI and 
oligodendrocytes/myelination may precede illness onset. Finally, it would be also worth 
investigating compounds such as sulforaphane (Shirai et al., 2012) that up-regulate Nrf2-
dependent phase II detoxification enzymes and antioxidant proteins which include the 
cystine/glutamate antiporter and enzymes of the GSH system (Lavoie et al., 2009).
5. Concluding remarks
Brain development is dependent upon sequences of events: proliferation, differentiation, 
migration, formation, and maturation of neuronal circuitry. The pace of development varies 
among brain structures, with the prefrontal cortex being the last to mature. Brain maturation 
mechanisms are under genetic control and influenced by environmental insults, suggesting 
that different brain regions could be vulnerable to a dysregulation of the “hub” during 
specific developmental periods. For instance, under a GSH deficit, the most susceptible 
periods for oxidative stress differ in the ACC, the ventral and dorsal hippocampus 
(Cabungcal et al., 2013a; Steullet et al., 2010). Moreover, inflammation induced at different 
prenatal periods can lead to distinct adult phenotypes (Meyer et al., 2008). Therefore, the 
timing of environmental insults during development combined with specific genetic 
vulnerability could differentially affect circuit connectivity and cognition, social 
competence, and affective behavior, leading to heterogeneous clinical phenotypes (Fig. 2).
The body of knowledge reviewed above suggests that it would be worth to intervene early 
during brain development on all three elements of the proposed “hub”. The genetic 
vulnerability factors, although important as potential biomarkers for high-risk individuals, 
may not lend themselves to therapeutic interventions. In contrast, we propose that targeting 
neuroinflammation, oxidative stress, and NMDAR hypofunction at critical developmental 
periods and early in the disease may reduce neuropathological anomalies and alleviate the 
risk of emergence of clinical manifestations.
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NAC N-acetylcysteine
PN pyramidal neuron
PNN perineuronal net
PVI parvalbumin interneurons
RNS reactive nitrogen species
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Fig. 1. 
Proposed “hub” formed of the redox, neuroimmune, and glutamatergic systems whose 
dysregulation during development could disrupt maturation of parvalbumin interneurons 
(PVI) and oligodendrocytes, two cell types affected in schizophrenia and critical for short- 
and long-range neuronal network synchronization. This could impact structural and 
functional connectivity circuits affecting diverse aspects of cognitive, affective and social 
functioning (Buckholtz and Meyer-Lindenberg, 2012). Genetic risk factors combined with 
environmental insults can affect the homeostasis of one or several of the “hub” systems 
which in turn could impact the others through reciprocal interactions (reciprocal arrows). 
Genetic vulnerability to redox dysregulation in schizophrenia is supported by 
polymorphisms and copy number variations in genes related to the GSH metabolism 
(Gravina et al., 2011; Gysin et al., 2007; Mehta et al., 2013; Rodriguez-Santiago et al., 2010; 
Tosic et al., 2006). In addition, impaired function of proteins coded by other plausible risk 
genes, including DISC1, PROD, G72, NRG, DTNBP1, indirectly leads to oxidative stress 
often via mitochondrial dysfunction (Clay et al., 2011; Gokhale et al., 2012; Goldshmit et 
al., 2001; Johnson et al., 2013; Krishnan et al., 2008; Park et al., 2010). Genes related to the 
immune system have also been identified as potent risk genes for schizophrenia, in 
particular the major histocompatibility complex (MHC) genes, one of the most replicated 
genetic risk factors for schizophrenia disorder (Smyth and Lawrie, 2013; Stefansson et al., 
2009). Finally, genetic vulnerability for NMDAR hypofunction seems to be more associated 
with potent risk genes encoding proteins that indirectly influence the function of this 
receptor; this includes d-amino acid oxidase, G72, dysbindin, and neuregulin (see Coyle et 
al., 2012), mGluR5 and proteins belonging to the postsynaptic NMDAR complex (Fromer et 
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al., 2014; Kirov et al., 2012; Purcell et al., 2014; Timms et al., 2013). Developmental insults 
that are known to increase the risk for schizophrenia cause redox dysregulation/oxidative 
stress (Do et al., 2009b; Walter et al., 2002) and/or neuroinflammation (Brenhouse and 
Andersen, 2011; Garate et al., 2013; Kaur et al., 2013; Schiavone et al., 2009). Note that the 
dopaminergic or serotoninergic (5-HT) systems (and others = X Y) modulated by risk-factor 
genes and environment could also impact micro- and macrocircuits either directly or 
indirectly via interactions with the above “hub”. Dotted arrows depict impact of genetic risk 
factors. E/I balance: excitatory/inhibitory balance; PNN: perineuronal net surrounding PVI.
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Fig. 2. 
The timing of environmental insults levied upon an individual (at risk) during his 
development, may determine which brain region microcircuits and which macrocircuits 
connecting distant brain areas are structurally and functionally affected. The period(s) of 
vulnerability of a micro- or macrocircuit may vary according to the genetic risk factors and 
the nature of the environmental stress and may be influenced by the developmental 
trajectory of other brain areas. In addition, microcircuits might be particularly susceptible 
prior to their final maturation during the period of enhanced plasticity. Therefore, the timing 
of environmental insults during development combined with specific genetic vulnerability 
could differentially affect circuit connectivity associated with sensory-motor function, social 
competence, affective behavior, and cognition leading to heterogeneous clinical phenotypes. 
An early insult could lead to more severe and wide-spectrum clinical phenotypes than a later 
insult.
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